CEO to participate in ARVO SIG panel on oral medications for retinal diseases
ZETA-1 Phase 2 clinical trial subset analysis to be presented during the ASRS 42nd Annual Scientific Meeting
CEO to participate in ARVO SIG panel on oral medications for retinal diseases
ZETA-1 Phase 2 clinical trial subset analysis to be presented during the ASRS 42nd Annual Scientific Meeting